Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Free Report) – Equities researchers at HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a research report issued on Monday, August 10th. HC Wainwright analyst S. Lee now anticipates that the company will earn ($0.23) per share for the quarter, down from their prior forecast of ($0.17). The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.74) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.83) EPS, Q1 2027 earnings at ($0.23) EPS, Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.18) EPS, Q4 2027 earnings at ($0.16) EPS, FY2027 earnings at ($0.80) EPS, FY2028 earnings at ($0.37) EPS and FY2029 earnings at ($0.01) EPS.
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03).
Read Our Latest Analysis on Corvus Pharmaceuticals
Corvus Pharmaceuticals Stock Performance
Shares of Corvus Pharmaceuticals stock opened at $14.73 on Wednesday. The company has a market capitalization of $1.24 billion, a PE ratio of -24.15 and a beta of 0.87. The company has a 50-day simple moving average of $13.51 and a two-hundred day simple moving average of $15.28. Corvus Pharmaceuticals has a one year low of $4.38 and a one year high of $26.95.
Hedge Funds Weigh In On Corvus Pharmaceuticals
Several hedge funds have recently made changes to their positions in CRVS. The Manufacturers Life Insurance Company grew its stake in Corvus Pharmaceuticals by 481.7% during the 1st quarter. The Manufacturers Life Insurance Company now owns 101,779 shares of the company’s stock valued at $1,489,000 after purchasing an additional 84,282 shares during the last quarter. Avidity Partners Management LP purchased a new position in shares of Corvus Pharmaceuticals in the first quarter worth about $1,682,000. Seven Fleet Capital Management LP acquired a new stake in shares of Corvus Pharmaceuticals during the first quarter worth about $1,213,000. Emerald Mutual Fund Advisers Trust purchased a new stake in Corvus Pharmaceuticals in the first quarter valued at approximately $6,719,000. Finally, Emerald Advisers LLC purchased a new stake in Corvus Pharmaceuticals in the first quarter valued at approximately $10,039,000. 46.64% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In related news, Director David Scott Moore purchased 21,700 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $11.53 per share, with a total value of $250,201.00. Following the completion of the acquisition, the director owned 21,700 shares in the company, valued at approximately $250,201. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 19.70% of the company’s stock.
Key Corvus Pharmaceuticals News
Here are the key news stories impacting Corvus Pharmaceuticals this week:
- Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior report, with a zero-day short-interest ratio. However, the accompanying “NaN” change indicates the data may be incomplete or unreliable, so it provides little actionable insight for investors.
- Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a loss of $0.83 from $0.66 and cut its 2027 forecast to a loss of $0.80 from $0.63. Quarterly estimates were also reduced, including Q3 2026 to a $0.23 loss from $0.17 and Q1–Q2 2027 to losses of $0.23 and $0.24, respectively. HC Wainwright earnings estimates
- Negative Sentiment: Longer-term projections also deteriorated: FY2028 EPS was cut to a $0.37 loss from $0.25, FY2029 was revised to a $0.01 loss from $0.07 profit, and FY2030 was reduced to $0.67 from $0.74. These changes indicate that expected earnings improvement and potential profitability may be arriving later than previously anticipated.
- Negative Sentiment: The revisions reinforce existing earnings risk: Corvus most recently reported a quarterly loss of $0.19 per share, missing the $0.16-loss consensus estimate. The company remains unprofitable, and analysts currently expect a full-year loss of approximately $0.74 per share.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.
Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.
Read More
- Five stocks we like better than Corvus Pharmaceuticals
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
